Depression patients with variations in two genes — GRIK4 and HTR2A — are more likely to respond to the medication citalopram (Forest’s Celexa) than are people without the variations, a study by the National Institute of Mental Health has found.

“The increased likelihood was small, but when people had both [the GRIK4] variation and one in a different gene [HTR2A] shown to have a similarly small effect in an earlier study, [patients] were 23 percent more likely to respond to citalopram than were people with neither variation,” NIMH says.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.

The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.

Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.

In Nature this week: ash dieback disease fungal genome, and more.